---
layout: default
title: Dimethicone
parent: 僅模型預測 (L5)
nav_order: 248
evidence_level: L5
indication_count: 10
---

# Dimethicone
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Dimethicone: From Skin Protection to Insomnia

## One-Sentence Summary

Dimethicone is an inert silicone polymer widely used as a topical skin protectant, emollient excipient, and antiflatulent agent; no formally registered therapeutic indications are documented in the current dataset.
The TxGNN model predicts it may be effective for **Insomnia**, with a prediction score of **94.35%** (rank 62,274 of all drug–disease pairs).
However, **no clinical trials and no supporting literature** currently exist to substantiate this prediction, placing the evidence at the lowest possible level (L5).

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | No registered indication on record |
| Predicted New Indication | Insomnia |
| TxGNN Prediction Score | 94.35% |
| Evidence Level | L5 |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known pharmacological properties, Dimethicone is an inert polydimethylsiloxane polymer. It acts purely through physical and mechanical means — forming a protective film on skin or mucosa, reducing surface tension of gas bubbles in the gastrointestinal tract — and has no known receptor-binding activity, no CNS penetration, and no systemic absorption under normal conditions.

Insomnia involves dysregulation of sleep-wake neurocircuitry, including GABAergic inhibition, adenosinergic tone, melatonin signalling, and monoaminergic modulation. Dimethicone does not interact with any of these pathways. There is no plausible pharmacological bridge between this inert excipient and sleep regulation.

The high TxGNN score (94.35%) is most likely attributable to indirect proximity effects within the knowledge graph — Dimethicone may share graph neighbours (e.g., shared drug-excipient relationships or broadly connected disease nodes) with compounds that do have CNS activity. This is considered a **computational false positive**, and the prediction should be treated with caution.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## India Market Information

Dimethicone (DrugBank ID: DB11074) currently has **no registered products** in the India regulatory database. No authorization numbers, brand names, or approved indications are on record.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
Dimethicone is a biologically inert silicone polymer with no known CNS activity, no blood-brain barrier permeability, and no receptor-level mechanism relevant to sleep disorders. The high TxGNN prediction score is attributed to knowledge graph clustering artefacts rather than genuine pharmacological signal. There is zero supporting clinical or preclinical evidence for this indication.

**To proceed, the following is needed:**
- Establish whether any modified or nano-formulated form of Dimethicone has demonstrated CNS-relevant activity in peer-reviewed preclinical studies
- Obtain full mechanism of action data from DrugBank (currently a data gap)
- Perform manual review of TxGNN knowledge graph paths to identify which intermediate nodes generated this score, and evaluate whether the path represents biological plausibility or graph noise
- If any biological rationale is identified in the above steps, a formal preclinical hypothesis and in vitro sleep-model study design would be the minimum next step before any clinical consideration

> **Research Disclaimer:** This report is generated for research reference purposes only and does not constitute medical advice. Drug repurposing candidates require clinical validation before any therapeutic application.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

